Immune Evasion in Pancreatic Cancer: from Mechanisms to Therapy<strong> </strong>

• DOI: 10.20944/preprints201712.0014.v1
• Publication Date: 2017-12-06T08:40:35Z
• Authors: Neus Martinez-Bosch; Judith Vinaixa; Pilar Navarro
• Keywords: Evasion (ethics); Cancer Immunotherapy

Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer, is one main unfinished businesses in biomedical and clinical fields, with still discouraging 5 year survival rates poor therapy efficiency. PDA abundant desmoplasia has for long played lead mechanisms involved drug performance, being source cytokines chemokines orchestrating rapid silent tumor progression guilty isolating cells into a extense fibrotic reaction resulting inefficient delivery. However, since immunotherapy was proclaimed breakthrough back to 2013, focus stroma cancer interestingly moved from activated fibroblasts immune compartment, trying understand immunosuppressive factors that play part strong evasion characterizes PDA. microenvironment highly immune-suppressive, basically composed T regulatory (Tregs), tumor-associated macrophages (TAMs) myeloid-derived suppressive (MDSCs), which boycott CD8+ T-cell duties recognition clearance. Interestingly, preclinical data have highlighted importance this as resistance single checkpoint immunotherapies vaccines point at pathways inhibiting attack key solve puzzle. Here, we will discuss molecular escape well state art immunotherapy.